INTRODUCTION
Diseases of the joint are a considerable global economic burden, accounting for 5 of completed the Oxford Shoulder Score (OSS), a validated and widely used clinical 9 9 outcome measure scoring from 0 (severe pathology) to 48 (normal function). aged between 20 and 45 (mean 27.2 ± 10 years). 1 1 0
Isolation of tendon-derived stromal cells from healthy and diseased tendons. 1 
1
Tendon derived stromal cells were isolated from the tendons of patients and healthy 1 1 2 volunteers using previously published protocols 12, 16 . For experiments, cells were 1 1 3 incubated in DMEM F12 media (Gibco) containing 1% heat inactivated human serum 1 1 4 (Sigma) and 1% Pen-Strep. Passage 1-3 cells were used for all experiments. We previously characterised tendon stromal cells as CD45 neg and CD34 neg cells 1 1 6 exhibiting fibroblast morphology 12 . Cytokine treatment of tendon-derived stromal cells 1 1 8 IL-1β is known to induce expression of NF-κB target genes highly expressed in 1 1 9 shoulder tendon disease 16 . We therefore investigated the bioactive LM profiles in 1 2 0 tendon-derived stromal cells isolated from the tendons of healthy volunteers and 1 2 1 patients in the presence of IL-1β (10 ngmL -1 , Sigma) in medium (DMEM F12 phenol containing 1% heat inactivated human serum (Sigma) and 1% penicillin- streptomycin. Cells were stimulated with IL-1β (10ngml -1 ) in the presence of media 1 3 5 containing either LXB 4 , RvE1 or vehicle control as previously described 15 . Parallel experiments were performed and cell lysates harvested to investigate if incubating 1 3 7 cells in these SPM moderated the expression of markers of the pro-inflammatory Bioactive LM profiling of media and lysate samples from IL-1β stimulated tendon cells was performed using previously described methodology 15 . Calibration curves were obtained for each using authentic compound mixtures and deuterium labelled were obtained for each LM, which gave r 2 values of 0.98-0.99. Immunocytochemistry for LXB 4 and RvE1 treated tendon stromal cells 1 4 9 Tendon stromal cells isolated from patients and healthy volunteers were grown in isolation, cDNA synthesis and quantitative PCR were performed using previously 1 7 4 published protocols 16 . Pre-validated Qiagen primer assays (ALOX15, ERV1, IL6, using the ddCt method using reference genes for human β -actin and GAPDH. 1 7 7 Results were consistent using these reference genes and data are shown normalized to β -actin. 1 7 9 Quantification of Interleukin-6 in tissue culture media 1 8 0 IL-6 is an important cytokine implicated in inflammation and is abundantly released
by tendon stromal cells isolated from patients with shoulder tendon tears after stimulation with IL-1β 15 . IL-6 in tissue culture supernatants was measured using analysis software. Phospho-signalling in LXB 4 and RvE1 treated tendon stromal cells 1 8 9 A human phospho-kinase array kit (R&D Systems ARY003B) was used to investigate the effects of incubating IL-1β stimulated patient derived tendon cells in harvested after 24h incubation in either LXB 4 or RvE1. Images were captured using 1 9 4 a chemiluminescence documentation system (UVITEC), and densitometry analysis 1 9 5 of proteins of interest was performed using ImageJ software (NIH). Statistical analyses were performed using GraphPad Prism 7 (GraphPad Software). presenting higher similarity in the data matrix). Loading plot interpretation identified the variables with the best discriminatory power (Variable Importance in Projection greater then 1) that were associated with tight clusters for LM profiles obtained from incubations with cells from healthy volunteers or patients with tendinopathy. For shown as summed with SEM, where n is the biological replicate. Unpaired t-tests
were used to test for differences in LM levels between tendon cells derived from U tests were used to determine differences in expression of proinflammatory and proresolving genes and IL-6 protein in IL-1β treated tendon stromal cells in the
presence or absence of LXB 4 , RvE1 or respective vehicle. P < 0.05 was considered 2 2 1 statistically significant. We previously identified that tendon stromal cells isolated from patients with shoulder tendon tears show dysregulated resolution responses compared to cells
isolated from healthy volunteer tendons 15 . This study identified SPM including LXB 4 and E series resolvins were differentially regulated in these incubations. To gain further insights into whether these SPM counter-regulate tendon inflammation, we of IL-1β stimulated tendon stromal cells isolated from the tendons of patients with differences in bioactive LM profiles between IL-1β stimulated tendon cells isolated from either healthy volunteer donors or patients with tendon tears in the presence of concentrations of the individual lipid mediators identified are listed in Table S1 . In tendon cells from healthy volunteers (p=0.008) and tendon tear patients (p=0.008) 2 4 3
( Figure 1E ). Multivariate analysis also identified distinct clustering of the LM profiles 2 4 4 between IL-1β stimulated tendon cells isolated from healthy volunteer donors and individual lipid mediators identified are listed in Table S1 . In these incubations, RvE1 upregulated concentrations of SPM in healthy volunteer tendon cells (p=0.008) and 1 2 stimulated tendon tear cells showed increased CHEMR23/ERV1mRNA compared to 2 6 8 respective healthy tendon cells ( Figure 3D ). Indeed, RvE1 treatment upregulated 2 6 9 the expression of ChemR23/ERV1 and BLT1 receptors in IL-1β stimulated tendon
tear cells compared to respective vehicle controls ( Figure 3E ). cells, dampening pro-inflammatory signalling pathways 2 7 4 We next assessed whether LXB 4 and RvE1 also regulated known markers of tendon 2 7 5 inflammation in tendon cells isolated from tendon tear patients and healthy to respective vehicle controls ( Figure 4A ). The same treatment of IL-1β stimulated 2 7 9 healthy tendon cells also reduced PDPN, STAT-1 and IL-6 compared to respective respectively, Figure 4D ). We next determined if LXB 4 or RvE1 treatment moderated mRNA expression compared to vehicle controls (p=0.004, p=0.002 and p=0.015 respectively, Figure 4E ). RvE1 treatment of IL-1β stimulated tendon tear cells also 2 8 9 reduced IL6, PDPN and CD90 mRNA compared to vehicle controls (p=0.02, p=0.02
and p=0.015 respectively, Figure 4E ). In these incubations, LXB 4 or RvE1 treatments regulated phospho-kinase signalling pathways identified in inflamed tendons, cell types driving chronic inflammatory joint disease 10, 18, 19 . After exposure to an phenotype exhibiting activation and inflammation memory 11, 12, 20 . Distinct fibroblast 3 0 4
subtypes that mediate joint inflammation and tissue damage have been improved understanding of how these cells respond to an inflammatory milieu is
required to inform the development of therapeutic strategies targeting these cells. We recently identified that tendon stromal cells isolated from patients with tendon tears showed increased levels of SPM and inflammation initiating eicosanoids dysregulated resolution response characteristic of chronic inflammation 15 . We also 3 1 5 identified that incubation of IL-1β stimulated tendon stromal cells in either 15-epi- release of SPM 15 . These treatments moderated the pro-inflammatory phenotype of 3 1 8 IL-1β stimulated diseased tendon stromal cells, dampening expression of PDPN, 3 1 9 STAT-1 and IL-6. We previously identified that SPM including LXB 4 and E series 3 2 0 resolvins were differentially regulated between IL-1β stimulated tendon cells isolated from these patient cohorts. Tendon stromal cells were stimulated with IL-1β, as this 3 2 5 cytokine is known to induce expression of NF-κB target genes highly expressed in human tendon disease 16, 20 , simulating an inflammatory milieu. In these incubations, stimulated diseased tendon cells. We next investigated the mechanism of action 3 3 0
underpinning these observations. Incubating in LXB 4 or RvE1 induced expression of stromal cells. Notably, expression of these SPM biosynthetic enzymes was 3 3 3 increased in diseased compared to healthy tendon stromal cells. We previously 3 3 4 identified that incubation of tendon stromal cells in 15-epi-LXA 4 or MaR1 induced 3 3 5 ALOX15 expression 15 . The findings from the current study support these 3 3 6 observations, suggesting a common mechanism whereby proresolving mediator 3 3 7 activate feed forward cascades leading to the upregulation of other SPM via induction of ALOX biosynthetic enzymes. We next investigated if incubating tendon ERV1 and a competitive inhibitor of BLT1 22, 23 . In the absence of SPM treatment, ERV1 mRNA expression was increased in diseased compared to healthy IL-1β 3 4 3 stimulated tendon stromal cells, suggesting a pro-inflammatory phenotype favours 3 4 4 increased expression of this proresolving receptor. Incubation of LXB 4 or RvE1 did 3 4 5 not induce ALX expression, although RvE1 treatment further upregulated ERV1 and 3 4 6 BLT1 expression on tendon stromal cells compared to vehicle treated cells. Collectively these findings suggest a positive feedback loop, whereby RvE1 direct consequence of RvE1 treatment, or via RvE1 induced upregulation SPM.
We identified that incubation in LXB 4 or RvE1 moderated the proinflammatory inflammation, including PDPN, CD90, STAT-1 and IL-6. CD90 is expressed by 3 5 3 pathogenic synovial fibroblasts from rheumatoid arthritis patients with an 3 5 4 inflammatory and invasive phenotype 21 . We previously identified persistent 3 5 5 fibroblast activation may be implicated in the development of chronic tendon 3 5 6 inflammation and increased likelihood of recurrent injury 12 . Proresolving mediators 3 5 7 may therefore possess therapeutic utility to moderate the pro-inflammatory and RvE1 regulate IL-6 via suppressing STAT-3 signalling in patient derived tendon 3 6 8 stromal cells. Suppression of STAT-6 signalling may modulate IL-4 and IL-13 3 6 9 responsive genes known to drive fibrosis in the advanced stages of tendon 16, 24 . IL-6 is an important cytokine implicated in the cross talk between macrophages, fibroblasts and infiltrating immune cells [25] [26] [27] . Given the ability of LXB 4 3 7 3 and RvE1 to regulate IL-6 release from IL-1β stimulated tendon cells, these SPM 3 7 4 may play an important role in dampening cytokine mediated cross-talk between 3 7 5 stromal cells which actively promotes the retention of immune cells. RvE1 treatment 3 7 6 also induced p70s6kinase signalling in IL-1β stimulated diseased tendon cells. RvE1 is also known to activate ERV-1 signalling via rs6 phosphorylation in peripheral blood 3 7 8 neutrophils isolated from patients with type 2 diabetes 28 . These findings suggest 3 7 9 that circulating immune cells and resident stromal fibroblasts share common Therapies that promote resolution of inflammation are an important future 3 8 3 therapeutic strategy to address pathogenic stroma in chronic inflammatory disease 3 8 4 of the joint. The pro-resolving mediator resolvin D3 (RvD3) has been shown to 3 8 5 regulate leukocyte infiltration pro-inflammatory eicosanoids in murine inflammatory infiltration, in acute murine inflammatory arthritis 30 . The current study suggests that Podoplanin, CD90, STAT-1, IL-6, and dampen phosphokinases including JNK1/2/3,
Lyn, STAT-3 and STAT-6. These SPM also potentiated further release of 3 9 1 proresolving mediators in IL-1β stimulated healthy and diseased tendon cells. We cells were derived from patients with shoulder tendon tears (TD, n=6) or healthy values. Representative images of immunocytochemistry for SPM synthetic enzymes represents POPO-1 nuclear counterstain. All images are representative of n=3 Representative images of immunocytochemistry for proresolving receptors ALX 4 6 8 (green), ERV1 (red) and BLT1 (violet) in IL-1β stimulated diseased tendon stromal 4 6 9 cells incubated in 10nM LXB 4, 10nM RvE1 or vehicle control for 24 hrs. Cyan tendon stromal cells. Tendon stromal cells were derived from patients with 4 7 5 shoulder tendon tears (TD) or healthy volunteers (HV). Representative images of 4 7 6 immunocytochemistry for established markers of tendon inflammation including 4 7 7 Podoplanin (PDPN) green, STAT-1 (green) and Interleukin-6 (IL-6, red) in IL-1β RvE1 or vehicle control for 24 hrs. Cyan represents POPO-1 nuclear counterstain. to identify the effects of incubating IL-1β treated TD cells in LXB 4 or RvE1 on protein phospho-kinase signalling pathways JNK1/2/3, Lyn, STAT3, STAT6 and 4 9 3 p70s6kinase. Results are shown as means and SEM and representative of n=3 4 9 4 donors per group relative to respective vehicle control treated cells. Figure S1. Isotype control staining of patient derived tendon stromal cells. 4 9 7 Representative confocal immunofluorescence images showing merged images of 4 9 8 stromal cells isolated from patients with shoulder tendon tears, stained with isotype control antibodies for mouse IgG 1 , IgG 2a , IgG 2b and rabbit IgG fractions. Cyan Tendon stromal cells (60,000 cells per well) were derived from patients with shoulder tendon tears (Diseased n=5 donors) or healthy volunteer hamstring tendons (Healthy n=5 donors) and incubated in the presence of 10nM LXB 4 , 10nM RvE1 or vehicle only in the presence of 10ngml -1 IL1β. Cell incubations were terminated using ice-cold methanol containing internal standards and lipid mediators (LM) were identified and quantified using LM-profiling (see methods for details). Results are expressed as pg/incubation. Mean ± SEM of n = 5 per incubation. * p ≤ 0.05 comparison between respective vehicle incubated tendon stromal cells. The detection limit was ~ 0.1 pg. 0.0, Below limits of detection.
